Trump urges pharma to split MMR vaccine, industry rejects proposal

A leading pharmaceutical company announced that it had rejected a set of recommendations issued by a regulatory body within just a few hours of their release. The recommendations, which were aimed at tightening safety protocols for the company’s upcoming oncology portfolio, were presented by the National Health Regulatory Authority (NHRA) in a public briefing held on Tuesday. The company’s spokesperson confirmed that the decision was made after an internal review of the proposed measures and the potential impact on ongoing clinical trials.

The NHRA had suggested that the firm adopt additional monitoring steps for patients receiving its new drug, including more frequent biomarker testing and extended post‑marketing surveillance. In response, the company cited concerns about the feasibility of implementing such protocols without delaying the drug’s launch and the need for further data to justify the additional costs. The spokesperson also indicated that the firm would continue to engage with the NHRA to explore alternative safety strategies that could satisfy regulatory expectations while maintaining the drug’s development timeline.

The rejection has prompted the NHRA to issue a statement reaffirming its commitment to patient safety and urging the company to provide a revised plan that addresses the authority’s concerns. Both parties have agreed to schedule a follow‑up meeting within the next month to discuss potential compromises. The outcome of these negotiations will likely influence the timeline for the drug’s approval and market entry.